Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.194 EUR | +2.23% | +2.23% | -7.30% |
Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
Business Summary
At the end of 2023, the company boasted a portfolio of 3 products in clinical development.
Number of employees: 63
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research
100.0
%
| 5 | 100.0 % | 5 | 100.0 % | -11.65% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 5 | 100.0 % | 5 | 100.0 % | -11.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Director of Finance/CFO | - | 08-04-30 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-08 |
Chief Operating Officer | - | - | |
Laurent Guerci
PRN | Corporate Officer/Principal | - | 23-07-11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 15-02-05 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Laura Coruzzi
BRD | Director/Board Member | 71 | 15-05-26 |
Karen Noël
BRD | Director/Board Member | 51 | 17-06-08 |
Emmanuel Huynh
CHM | Chairman | 54 | 19-08-25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 32,459,012 | 22,076,290 ( 68.01 %) | 253,928 ( 0.7823 %) | 68.01 % |
Company contact information
ABIONYX Pharma SA
33-43, avenue Georges Pompidou Bâtiment D2
31130, Balma
+33 5 62 24 97 06
http://www.abionyx.comSector
Sales per Business
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.30% | 40.76M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.20% | 21.97B | |
-4.64% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- ABNX Stock
- Company ABIONYX Pharma